China Traditional Chinese Medicine (SEHK:570) Half Year Loss Challenges Turnaround Narrative

Simply Wall St.03-22

China Traditional Chinese Medicine Holdings (SEHK:570) has reported its FY 2025 first half results with revenue of C¥7.5b and a basic EPS loss of C¥0.02, while the trailing twelve months show revenue ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621791718?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","is_english":true,"pubTime":"2026-03-22 03:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621791718","market":"us","top_or_hot":-1,"title":"China Traditional Chinese Medicine (SEHK:570) Half Year Loss Challenges Turnaround Narrative","media":"Simply Wall St.","content":"<div>\n<p>China Traditional Chinese Medicine Holdings (SEHK:570) has reported its FY 2025 first half results with revenue of C¥7.5b and a basic EPS loss of C¥0.02, while the trailing twelve months show revenue ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-570/china-traditional-chinese-medicine-holdings-shares/news/china-traditional-chinese-medicine-sehk570-half-year-loss-ch\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Traditional Chinese Medicine (SEHK:570) Half Year Loss Challenges Turnaround Narrative</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Traditional Chinese Medicine (SEHK:570) Half Year Loss Challenges Turnaround Narrative\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-22 03:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-570/china-traditional-chinese-medicine-holdings-shares/news/china-traditional-chinese-medicine-sehk570-half-year-loss-ch><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>China Traditional Chinese Medicine Holdings (SEHK:570) has reported its FY 2025 first half results with revenue of C¥7.5b and a basic EPS loss of C¥0.02, while the trailing twelve months show revenue ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-570/china-traditional-chinese-medicine-holdings-shares/news/china-traditional-chinese-medicine-sehk570-half-year-loss-ch\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-570/china-traditional-chinese-medicine-holdings-shares/news/china-traditional-chinese-medicine-sehk570-half-year-loss-ch","article_id":"2621791718","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-570/china-traditional-chinese-medicine-holdings-shares/news/china-traditional-chinese-medicine-sehk570-half-year-loss-ch","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621791718","pubTimestamp":1774120142,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"China Traditional Chinese Medicine Holdings (SEHK:570) has reported its FY 2025 first half results with revenue of C¥7.5b and a basic EPS loss of C¥0.02, while the trailing twelve months show revenue of C¥14.7b and a basic EPS loss of C¥0.07. Over recent half year periods, revenue has moved from C¥8.4b with EPS of C¥0.04 in 1H 2024 to C¥8.1b with an EPS loss of C¥0.03 in 2H 2024, then to C¥7.5b with an EPS loss of C¥0.02 in 1H 2025, setting up a story where investors are weighing weaker...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","BK1606":"中医药概念","00570":"中国中药","BK1515":"抗疫概念"},"translate_title":"中国中药(SEHK：570)半年亏损挑战扭亏为盈叙事","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00570":0.9},"content_text":"China Traditional Chinese Medicine Holdings (SEHK:570) has reported its FY 2025 first half results with revenue of C¥7.5b and a basic EPS loss of C¥0.02, while the trailing twelve months show revenue of C¥14.7b and a basic EPS loss of C¥0.07. Over recent half year periods, revenue has moved from C¥8.4b with EPS of C¥0.04 in 1H 2024 to C¥8.1b with an EPS loss of C¥0.03 in 2H 2024, then to C¥7.5b with an EPS loss of C¥0.02 in 1H 2025, setting up a story where investors are weighing weaker earnings against potential future growth. Overall, margins remain under pressure, so the key question is how quickly profitability can be rebuilt from here. See our full analysis for China Traditional Chinese Medicine Holdings. With the latest figures on the table, the next step is to see how this margin picture lines up with the widely followed bull and bear narratives around the stock and where those stories might need a reset. Curious how numbers become stories that shape markets? Explore Community Narratives SEHK:570 Revenue & Expenses Breakdown as at Mar 2026 AdvertisementLosses Continue With C¥342m TTM Shortfall  On a trailing twelve month basis to 2H 2025, total revenue sits at C¥14.7b while net income excluding extra items is a loss of C¥342.07m, compared with a loss of C¥264.83m on C¥15.6b of revenue one half earlier in the dataset. What stands out for a bearish reading is that losses appear larger over the trailing periods even as revenue remains in the mid teens billions of yuan. This aligns with the risk summary, which highlights that losses have grown at about 43.8% per year over five years and net margin remains negative.\n     Bears highlight that 1H 2025 shows a C¥107.92m net loss excluding extra items on C¥7.5b of revenue, following a C¥156.91m loss on C¥8.1b in 2H 2024 and a swing from C¥210.98m profit on C¥8.4b in 1H 2024. That pattern of profit in early 2024 turning into losses on a trailing basis is consistent with the analysis that the company is currently unprofitable and that negative margins are a key risk to any value argument.    Stay grounded in the numbers before forming a view on any turnaround story, especially when trailing losses are this visible.🐻 China Traditional Chinese Medicine Holdings Bear Case P/S At 0.6x Versus 3.1x Industry  The valuation input shows a P/S multiple of 0.6x for China Traditional Chinese Medicine Holdings, compared with 3.1x for the Hong Kong pharmaceuticals industry and 9.2x for the peer group, while the current share price is HK$1.88. Supporters of a bullish case often point to this wide valuation gap and the cited DCF fair value of HK$4.87, arguing the stock trades at a steep discount. However, the same dataset also notes that the company is still loss making on a trailing view, so the low multiple is paired with negative earnings.\n     The reward summary describes the stock as inexpensive on sales based metrics and flags a modeled DCF fair value that is more than double the prevailing price, which is a clear part of the positive thesis. At the same time, the risk section explicitly notes ongoing unprofitability and five year loss growth, so anyone leaning on the 0.6x P/S and DCF inputs needs to weigh those against the C¥342.07m trailing loss and negative margins shown in the latest financials.    Revenue Forecast At 4.5% A Year  The analysis input states that revenue growth is forecast at 4.5% per year, below a referenced Hong Kong market forecast of 8.3% a year, while earnings are projected in that dataset to grow very quickly and move the company into profitability within three years. For a bullish narrative check, it is notable that the projections expect earnings to grow at about 113.8% a year and eventually turn positive even though the trailing twelve month figures still show a C¥342.07m net loss on C¥14.7b of revenue. The story therefore rests on a shift from the current loss profile to the modeled path in the forecasts.\n     The last three half year data points move from C¥210.98m profit in 1H 2024 to losses of C¥156.91m in 2H 2024 and C¥107.92m in 1H 2025, which sets a very different backdrop than the strong forward earnings growth implied in the inputs. Because the same summary also mentions that revenue growth is expected to trail the wider market, the bullish angle leans more on margin improvement and profitability turning around than on top line expansion alone.    If you want to see how other investors connect these growth forecasts, losses and valuation metrics into a single story, check out the wider range of community views.📊 Read the what the Community is saying about China Traditional Chinese Medicine Holdings. Next Steps Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on China Traditional Chinese Medicine Holdings's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move. If the mix of risks and potential rewards feels finely balanced, quickly review the numbers yourself and test whether they fit your goals, then take a closer look at the 3 key rewards See What Else Is Out There China Traditional Chinese Medicine Holdings is wrestling with ongoing losses, pressured margins and forecasts that rely heavily on a future earnings turnaround rather than current profitability. If you want ideas where pricing may already reflect stronger financial footing and less earnings strain, start comparing opportunities using the 284 resilient stocks with low risk scores.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621791718","isCrawlerRequest":true}